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Abstract: The atherogenic index of plasma (AIP), composed of triglycerides and high-density lipopro-
tein cholesterol, is a novel critical marker for assessing the risk of atherogenicity and cardiometabolic
health. We aimed to prospectively study the association between AIP and incident ischemic heart dis-
ease (IHD) risk in a large cohort of non-diabetic Korean adults. Data were assessed from 17,944 partici-
pants without diabetes from the Health Risk Assessment Study (HERAS) and Korea Health Insurance
Review and Assessment (HIRA) data. The participants were divided into four groups according to
AIP quartiles, calculated as log (triglyceride/high-density lipoprotein cholesterol). We prospectively
assessed hazard ratios (HRs) with 95% confidence intervals (CIs) for IHD using multivariate Cox
proportional-hazard regression models over a 50-month period that followed the baseline survey.
During the follow-up period, 332 participants (1.9%) developed IHD. HRs of IHD for AIP quartiles
2–4 were 1.58 (95% CI, 1.03–2.43), 1.82 (95% CI, 1.20–2.78), and 2.11 (95% CI, 1.37–3.24) after adjust-
ing for age, sex, body mass index, smoking status, alcohol intake, physical activity, mean arterial
blood pressure, fasting plasma glucose, high-sensitivity C-reactive protein level, and hypertension
medication. Higher AIP levels may precede and predict the development of IHD in non-diabetic
Korean adults.
Keywords: atherogenic index of plasma; triglycerides; cardiometabolic risk; cohort study; ischemic
heart disease
1. Introduction
In the early twenty-first century, cardiovascular disease (CVD) has become the lead
cause of death. Among CVDs, ischemic heart disease (IHD) affects as many as 126 million
people, accounting for an estimate of 1.72% of the global population [1–3]. IHD is also
the leading cause of death in Korea and has increased gradually over the last decade with
rapid population aging [4]. Thus, the emphasis should be placed on screening high-risk
individuals and taking appropriate preventative measures to control the occurrence of
IHD events.
Among conventional risk factors of CVD, an abnormal plasma lipid profile is consid-
ered to be an important risk factor for IHD [5–8]. Clinical emphasis was placed on elevated
triglyceride (TG) levels because high TG was found to be an independent risk factor for
IHD in previous epidemiological studies [9–12]. Increasing TG affects the low-density
lipoprotein cholesterol (LDL-C) particle phenotype to be smaller, denser, and more easily
oxidized, elevating atherogenic potential [13–15]. Additionally, the TG and IHD relation-
ship is known to be mediated partly by the concentration of high-density lipoprotein
cholesterol (HDL-C) because, within the high TG concentration range, decreasing HDL
was shown to be associated with an increased risk of IHD [14,16–19]. The central lipid
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parameters: TG and HDL-C are utilized in a calculated value called the atherogenic index
of plasma (AIP). AIP has been gaining prominence as a screening tool for dyslipidemia
and is regarded as a major cardiometabolic risk factor [20]. The elevated AIP has been
shown to play an important role in the pathophysiology of both prehypertension and
prediabetes [21–23]. Additionally, studies have shown that non-diabetic individuals with
IHD had worse prognosis than diabetic patients without IHD [24,25].
This prompts the need for early detection of cardiometabolic risks that can contribute
to the development and progression of IHD. To our knowledge, information on the associa-
tion between AIP and IHD is limited. In this prospective study, the association between
AIP and IHD incidence was investigated within a large-scale, non-diabetic adult cohort
exported from the National Health Insurance Service data.
2. Materials and Methods
2.1. Study Design
The present study is a derivative of the Health Risk Assessment Study and Korea
Health Insurance Review and Assessment Service (HERAS-HIRA) cohort conducted be-
tween November 2006 and June 2010 [26]. The dataset was composed of 20,530 volunteers
sequentially visiting for health examination screenings at the Gangnam Severance Hos-
pital of the Yonsei University Health System. Participants meeting any of the following
criteria were excluded: a history of IHD; a history of ischemic stroke; previously diag-
nosed or newly diagnosed diabetes [27]; dyslipidemia medication; or current use of aspirin
(Figure 1).
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Figure 1. Study population selection. i re 1. St o latio selectio .
We examined health behaviors and past medical history through structured ques-
tionnaires for every participant. The medical staff measured systolic blood pressure (SBP)
and diastolic blood pressure (DBP) with arms supported at the heart level, sitting position
using mercury sphygmomanometers after 10 min of rest (Baumanometer, Baum Co Inc.,
Nutrients 2021, 13, 3231 3 of 9
Copiague, NY, USA). We defined hypertension as SBP ≥ 140 mmHg, DBP ≥ 90 mmHg, a
history of hypertension previously diagnosed by a doctor, or current use of antihyperten-
sive medication [28]; defined impaired fasting glucose (IFG) as a fasting plasma glucose
(FPG) from 100 to 125 mg/dL [29]; defined metabolic syndrome as at least three of the
following medical conditions: body mass index (BMI) ≥ 25.0 kg/m2, SBP ≥ 130 mmHg,
DBP ≥85 mmHg, or use of blood pressure-lowering drugs; FPG levels ≥ 100 mg/dL or use
of antidiabetic agents; TG ≥ 150 mg/dL; and HDL-C < 40 mg/dL for men and <50 mg/dL
for women [30]. The formula for calculating AIP was as follows: the base-ten logarithm of
the plasma concentration ratio of TG to HDL-C [31].
2.2. Outcomes
The outcomes were acute myocardial infarction (ICD-10 code I21) or angina pectoris
(ICD-10 code I20) since the study enrollment [26]. We conduct outcomes assessment over
the 50 months since the initial registration by linking each unique 13-digit identification
number to the HIRA database.
2.3. Statistics
We divided the AIP values into quartiles and compared the clinical characteristics at
the baseline. To evaluate the cumulative IHD incidence, we used Kaplan–Meier curves
with the log-rank test. We performed multivariate Cox proportional-hazard regression
models to assess hazard ratios (HRs) with 95% confidence intervals (CIs) for IHD after
adjusting for potential confounding factors, using SAS version 9.4 (SAS Institute Inc., Cary,
NC, USA).
3. Results
Table 1 shows the baseline characteristics of the study population (n = 17,944; 9153 men
and 8791 women) based on the AIP quartiles. The mean age, HDL-C, TG, and AIP values
were 44.7 ± 10.5 years, 1.4 ± 0.9 mmol/L, 1.4 ± 0.3 mmol/L, and −0.06 ± 0.29, respectively.
The subjects with the highest AIP quartile showed the highest BMI, mean arterial pressure,
fasting blood glucose, hsCRP, and total cholesterol levels, as well as the lowest mean
HDL-C levels. Additionally, this group had the highest proportions of alcohol drinkers
and current smokers, as well as the lowest proportion of individuals involved in regular
exercise. The incidence of impaired fasting glucose, hypertension, and metabolic syndrome
were 17.2%, 19.7%, and 11.5%, respectively, which gradually increased according to the
AIP quartiles.









n = 4475 p Value
1 Post Hoc 2
AIP ≤−0.27 −0.26 to −0.08 −0.07 to 0.14 ≥ 0.15
Age (years) 42.3 ± 10.5 44.6 ± 10.6 46.1 ± 10.4 45.9 ± 10.0 <0.001 a,b,c,d,e
Male sex (%) 24.4 42.4 60.6 76.5 <0.001 -
Body mass index (kg/m2) 21.4 ± 2.5 22.6 ± 2.7 23.9 ± 2.8 25.1 ± 2.8 <0.001 a,b,c,d,e,f
Systolic blood pressure (mmHg) 115.4 ± 14.3 119.8 ± 15.1 123.8 ± 14.9 127.8 ± 14.7 <0.001 a,b,c,d,e,f
Diastolic blood pressure (mmHg) 71.7 ± 9.3 74.6 ± 9.8 77.3 ± 9.8 80.1 ± 9.6 <0.001 a,b,c,d,e,f
Mean arterial pressure (mmHg) 86.2 ± 10.6 89.7 ± 11.2 92.8 ± 11.1 96.0 ± 10.9 <0.001 a,b,c,d,e,f
Fasting plasma glucose (mmol/L) 4.9 ± 0.5 5.0 ± 0.5 5.1 ± 0.5 5.2 ± 0.6 <0.001 a,b,c,d,e,f
Total cholesterol (mmol/L) 4.7 ± 0.8 4.8 ± 0.8 5.0 ± 0.9 5.2 ± 0.9 <0.001 a,b,c,d,e,f
Triglyceride (mmol/L) 0.7 ± 0.1 1.0 ± 0.2 1.4 ± 0.3 2.5 ± 1.2 <0.001 a,b,c,d,e,f
HDL-cholesterol (mmol/L) 1.7 ± 0.3 1.5 ± 0.2 1.3 ± 0.2 1.1 ± 0.2 <0.001 a,b,c,d,e,f
C-reactive protein (mg/L) 0.9 ± 2.6 1.3 ± 3.4 1.6 ± 5.1 1.7 ± 3.5 <0.001 a,b,c,d,e
Current smoker (%) 11.0 18.7 28.2 41.3 <0.001 -










n = 4475 p Value
1 Post Hoc 2
Alcohol drinking (%) 3 36.1 41.3 45.7 52.5 <0.001 -
Regular exercise (%) 4 32.1 32.7 30.1 26.1 <0.001 -
Hypertension (%) 10.0 15.4 22.8 30.5 <0.001 -
Impaired fasting glucose (%) 7.9 13.2 20.0 27.6 <0.001
Metabolic syndrome (%) 0.6 2.1 7.3 36.1 <0.001 -
1 p values were calculated using one-way ANOVA or Pearson’s chi-square test. 2 Post hoc analysis with the Bonferroni method: a, Q1
versus Q2; b, Q1 versus Q3; c, Q1 versus Q4; d, Q2 versus Q3; e, Q2 versus Q4; and f, Q3 versus Q4. 3 Alcohol intake ≥ 140 g/week.
4 Moderate-intensity physical exercise ≥ three times/week.
Table 2 shows the overall incidence of IHD according to AIP quartiles during the
50-month follow-up period. During this time, 332 (1.9%, 332/17,944) subjects developed
IHD. The IHD incidence rate (per 1000 person-years) was positively related with AIP
quartiles. The higher AIP quartiles showed a significantly increased cumulative IHD
incidence over the follow-up period after the baseline survey (log-rank test, p < 0.001)
(Figure 2).
Table 2. Overall incidence of ischemic heart disease according to the atherogenic index of plasma
(AIP) quartiles.
New Cases of Ischemic







Q1 38 2.3 ± 1.1 10,550 3.6
Q2 73 2.4 ± 1.1 10,331 7.1
Q3 98 2.3 ± 1.1 10,752 9.1
Q4 123 2.4 ± 1.1 10,700 11.5
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Using univariate and multivariate Cox proportional hazards regression analysis, AIP
was correlated with new onset IHD in Tables 3 and 4. Compared to the HRs of the first AIP
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quartile (which was used as a reference), the HRs of new onset IHD for the second, third,
and fourth quartiles increased proportionately with the degree of AIP. After adjusting
for age and sex in Model 1, the HRs for incident IHD were 1.63 (95% CI, 1.10–2.42), 1.85
(95% CI, 1.27–2.71), and 2.34 (95% CI, 1.61–3.40) in the second, third, and fourth AIP
quartiles, respectively. Likewise, these longitudinal positive relationships were observed in
both Models 2 and 3, where additional adjustments were made for BMI, current smoking,
drinking, regular exercise, mean blood pressure, FPG, high-sensitivity C-reactive protein
levels, and hypertension medication. The adjusted HR for the highest versus lowest AIP
quartile was 2.11 (95% CI, 1.37–3.24) in Model 3. These associations were similar among
the male individuals but less prominent than the entire population (Table 5).
Table 3. Univariate Cox proportional-hazards regression model for incident ischemic heart dis-
ease (IHD).
HRs 95% CIs p Value
Age, years 1.071 1.061–1.081 <0.001
Male sex, yes or no 1.614 1.291–2.018 <0.001
Body mass index, kg/m2 1.100 1.065–1.137 <0.001
Systolic blood pressure, mmHg 1.017 1.010–1.023 <0.001
Diastolic blood pressure, mmHg 1.025 1.015–1.036 <0.001
Fasting plasma glucose, mg/dL 1.034 1.024–1.045 <0.001
Triglyceride, mg/dL 1.001 1.001–1.002 <0.001
HDL-cholesterol, mg/dL 0.978 0.969–0.987 <0.001
C-reactive protein, mg/L 1.012 0.993–1.031 0.218
Current smoker, yes or no 1.140 0.854–1.521 0.374
Alcohol drinking, yes or no 0.722 0.573–0.909 0.006
Regular exercise, yes or no 1.499 1.193–1.803 <0.001
Atherogenic Index of Plasma (AIP)
quartiles, Q1 vs. Q4 3.210 2.231–4.628 <0.001
Table 4. Hazard ratios and 95% confidence intervals for new-onset ischemic heart disease (IHD) according to atherogenic
index of plasma (AIP) quartiles.
Q1 Q2 Q3 Q4 p for Trend
Model 1 HR (95% CI) 1.00 (reference) 1.63 (1.10–2.42) 1.85 (1.27–2.71) 2.34 (1.61–3.40) <0.001
p value 0.015 0.001 <0.001
Model 2 HR (95% CI) 1.00 (reference) 1.59 (1.04–2.45) 1.87 (1.23–2.84) 2.21 (1.45–3.39) 0.003
p value 0.033 0.003 <0.001
Model 3 HR (95% CI) 1.00 (reference) 1.58 (1.03–2.43) 1.82 (1.20–2.78) 2.11 (1.37–3.24) 0.007
p value 0.037 0.005 <0.001
Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, body mass index, smoking status, alcohol intake, and physical activity.
Model 3: adjusted for age, sex, body mass index, smoking status, alcohol intake, physical activity, mean arterial blood pressure, fasting
plasma glucose, high-sensitivity C-reactive protein level, and hypertension medication.
Table 5. Hazard ratios and 95% confidence intervals for new-onset ischemic heart disease (IHD) according to atherogenic
index of plasma (AIP) quartiles only in the male population.
Q1 Q2 Q3 Q4 p for Trend
Model 1 HR (95% CI) 1.00 (reference) 1.54 (0.85–2.80) 1.88 (1.07–3.30) 2.28 (1.32–3.94) 0.013
p value 0.158 0.027 0.003
Model 2 HR (95% CI) 1.00 (reference) 1.43 (0.78–2.62) 1.71 (0.96–3.03) 1.89 (1.06–3.37) 0.147
p value 0.244 0.068 0.030
Model 3 HR (95% CI) 1.00 (reference) 1.43 (0.78–2.62) 1.65 (0.93–2.94) 1.79 (1.00–3.19) 0.238
p value 0.245 0.087 0.049
Model 1: adjusted for age. Model 2: adjusted for age, body mass index, smoking status, alcohol intake, and physical activity. Model 3:
adjusted for age, body mass index, smoking status, alcohol intake, physical activity, mean arterial blood pressure, fasting plasma glucose,
high-sensitivity C-reactive protein level, and hypertension medication.
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4. Discussion
This study revealed that elevated AIP values had positive and independent association
with the IHD incidence. After making adjustments for potentially confounding factors, the
results clearly demonstrated the linear association between an elevated AIP and the risk
of IHD.
Several surrogate markers of dyslipidemia for predicting atherosclerosis and CVD
have been investigated in clinical practice. Thus far, high fasting TG is the strongest
independent risk factor for IHD at all levels of HDL-C. Within the high TG level, high
HDL-C levels showed lower IHD risk compared to those with low HDL-C levels. This
meant that the high-TG and low-HDL-C concentration was the strongest risk factor for IHD,
while low-TG and high-HDL-C concentrations had a three times lower risk of IHD [13].
Similarly, our study also showed a trend of increasing TG and decreasing HDL-C as the
incidence of IHD increased. This finding is biologically plausible because increasing TG
levels cause an elevated production of TG-rich atherogenic lipoproteins, thus linearly
increasing the IHD risk despite consideration of the anti-atherogenic effects of HDL-C. AIP,
a calculated value that utilizes the two central lipid parameters, reflects the distribution
of particle sizes in lipoprotein subclasses, making AIP a great surrogate and independent
predictor of atherosclerosis and all-cause mortality [32–35]. Wu et al. also found that AIP
is a superior predictor of the coronary artery disease (CAD) risk than isolated levels of
lipid parameters [36]. In addition, AIP also correlates significantly with the traditional
risk factors for atherosclerosis and the CAD severity [36,37]. This mechanism may explain
why isolated hypercholesterolemia had no correlation to a high risk of IHD; instead, the
relevance of AIP was shown to be higher concerning the risk of IHD.
Accumulating evidence supports the role of AIP as a predictive index for both CVD
and metabolic syndrome (MetS) and type 2 diabetes [38,39]. MetS is a syndrome of multiple
abnormalities in glucose and lipid metabolism which induce hypertension, dyslipidemia,
glucose intolerance, and insulin resistance (IR) [40–43]. Many risk factors for MetS are
similar to those of IHD [44]. This was confirmed by many epidemiological studies that
revealed the association and showed that MetS presence predicted the risk of IHD in
the clinical field [45,46]. This trend of association was also observed in our study, where
metabolic syndrome increased with increasing AIP quartiles. Due to the well-established
association between IHD and diabetes, it is also important to examine how AIP is related
to well-known markers of IR in the presence of IHD. A well-established index of both
CVD and IR is the triglyceride-glucose (TyG) index, the natural logarithm (Ln) of the
product of plasma glucose and TG. The TyG index has been suggested to have a positive
association with a higher prevalence of CVD, and it has also been used in healthy adults as
a surrogate of IR [47,48]. Similar to the TyG index, AIP has recently been considered to be
an independent predictor of subclinical coronary artery disease [49]. Since TG and HDL-C
levels can be used as the basis for identification of IR and IHD, elevated AIP can predict the
trends of common risk factors such as low physical activity, high BMI, hypertension, type
2 diabetes, and elevated FPG levels. Several studies indicate that atherosclerosis-related
adverse events frequently occur in populations with low CV risk burden as well as those
with high CV risk [50–52]. This may emphasize the need for detecting and screening for
the elevation in atherogenic risk and predicting IHD in clinical practice. Therefore, this
need can be met by utilizing AIP as a clinical tool.
Because high AIP values are associated with a high risk of IHD, persons with high
AIP values must strive for lifestyle changes and periodically monitor their lipid profile
changes. Lifestyle changes and dietary regimens will also help with weight loss, lowering
TG levels, and increasing HDL levels. Pharmacological treatment to control lipid levels can
also be considered depending on how an individual’s lipid profile trends. CVD is known
to have gender differences in presentation, prevalence, and clinical outcomes [53–55]. For
instance, men and postmenopausal women showed an increased risk of IHD compared to
premenopausal women [56]. It is thought that postmenopausal women have atherogenic
LDL profiles comparable to those in men because of aging and the event of menopause [57].
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Our study findings also revealed that the higher the AIP quartile, the higher the percentage
of men in the highest quartile group. Thus, AIP seems to be a good atherogenic index that
is in concordance with the gender differences in IHD. Furthermore, there should be studies
evaluating treatment strategies for individuals with high AIP values.
The strength of our study is that we lead a prospective cohort study of Korean adults
who were linked to the HIRA data, which were derived from the national insurance
coverage system. However, our study also had some limitations. First, the study cohort
was comprised of volunteers in a single hospital setting and they visited for the purpose of
health promotion screenings. This may have produced a bias, referred to as the healthy
volunteer effect. It is worth mentioning that the majority of the patients who visit the
hospital are residents of Seoul city, the wealthiest city in South Korea. It is highly likely
that the distribution of participants’ economic status and education level is shifted. Thus,
there may have been confounding variables that were not considered at baseline. Second,
there is a chance that some diabetic patients were accidentally included in the study cohort
since glycated hemoglobin A1c and 2-h oral glucose tolerance tests were not initially
performed. Thus, this may have influenced the study’s results and interpretation. Third,
the shortcoming of the AIP score is that it can have significant variability in different
populations [37]. Thus, future investigations are necessary to determine the clinical range
of diagnostic AIP values in the Korean population.
5. Conclusions
This study identified that elevated AIP is a solid and useful predictor of IHD in
the non-diabetic Korean population. In addition, AIP was demonstrated to have good
predictive power for IHD compared to isolated TG level or other lipid parameters, in
addition to increasing recognition for being a robust and independent value stratifying
multiple cardiometabolic risks.
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